These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 31057118)

  • 21. Initial injectable therapy in type 2 diabetes: Key considerations when choosing between glucagon-like peptide 1 receptor agonists and insulin.
    Alexopoulos AS; Buse JB
    Metabolism; 2019 Sep; 98():104-111. PubMed ID: 31255662
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacogenetics of Glucagon-like Peptide-1 Agonists for the Treatment of Type 2 Diabetes Mellitus.
    Karras SN; Rapti E; Koufakis T; Kyriazou A; Goulis DG; Kotsa K
    Curr Clin Pharmacol; 2017; 12(4):202-209. PubMed ID: 29473524
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Glucagon-like peptide-1 receptor agonists: the key to healthy weight loss maintenance?
    Lehmann EW; Torekov SS
    Cardiovasc Res; 2021 Aug; 117(10):e120-e122. PubMed ID: 34448813
    [No Abstract]   [Full Text] [Related]  

  • 24. Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and meta analysis.
    Deacon CF; Mannucci E; Ahrén B
    Diabetes Obes Metab; 2012 Aug; 14(8):762-7. PubMed ID: 22471248
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Molecular mechanisms by which GLP-1 RA and DPP-4i induce insulin sensitivity.
    Yaribeygi H; Sathyapalan T; Sahebkar A
    Life Sci; 2019 Oct; 234():116776. PubMed ID: 31425698
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Primary care management of type 2 diabetes: a comparison of the efficacy and safety of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors.
    Campos C; Unger J
    Postgrad Med; 2021 Nov; 133(8):843-853. PubMed ID: 34416133
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cardiac resynchronization therapy with a defibrillator (CRTd) in failing heart patients with type 2 diabetes mellitus and treated by glucagon-like peptide 1 receptor agonists (GLP-1 RA) therapy vs. conventional hypoglycemic drugs: arrhythmic burden, hospitalizations for heart failure, and CRTd responders rate.
    Sardu C; Paolisso P; Sacra C; Santamaria M; de Lucia C; Ruocco A; Mauro C; Paolisso G; Rizzo MR; Barbieri M; Marfella R
    Cardiovasc Diabetol; 2018 Oct; 17(1):137. PubMed ID: 30348145
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Adding prandial GLP-1 receptor agonists to basal insulin: a promising option for type 2 diabetes therapy.
    Goldenberg RM; Berard L
    Curr Med Res Opin; 2018 Jan; 34(1):1-10. PubMed ID: 28836861
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tirzepatide: a glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) dual agonist in development for the treatment of type 2 diabetes.
    Frías JP
    Expert Rev Endocrinol Metab; 2020 Nov; 15(6):379-394. PubMed ID: 33030356
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The effect of glucagon-like peptide-1 receptor agonists on serum uric acid concentration: A systematic review and meta-analysis.
    Najafi S; Bahrami M; Butler AE; Sahebkar A
    Br J Clin Pharmacol; 2022 Aug; 88(8):3627-3637. PubMed ID: 35384008
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immunohistochemical assessment of glucagon-like peptide 1 receptor (GLP-1R) expression in the pancreas of patients with type 2 diabetes.
    Kirk RK; Pyke C; von Herrath MG; Hasselby JP; Pedersen L; Mortensen PG; Knudsen LB; Coppieters K
    Diabetes Obes Metab; 2017 May; 19(5):705-712. PubMed ID: 28094469
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Incretin-based therapies.
    Neumiller JJ
    Med Clin North Am; 2015 Jan; 99(1):107-29. PubMed ID: 25456646
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Glucagon-like peptide-1 receptor agonists in type 2 diabetes treatment: are they all the same?
    Gentilella R; Pechtner V; Corcos A; Consoli A
    Diabetes Metab Res Rev; 2019 Jan; 35(1):e3070. PubMed ID: 30156747
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A novel GIP analogue, ZP4165, enhances glucagon-like peptide-1-induced body weight loss and improves glycaemic control in rodents.
    Nørregaard PK; Deryabina MA; Tofteng Shelton P; Fog JU; Daugaard JR; Eriksson PO; Larsen LF; Jessen L
    Diabetes Obes Metab; 2018 Jan; 20(1):60-68. PubMed ID: 28598027
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety and tolerability of glucagon-like peptide-1 receptor agonists: unresolved and emerging issues.
    Raccah D
    Expert Opin Drug Saf; 2017 Feb; 16(2):227-236. PubMed ID: 27924636
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Characteristics and types of GLP-1 receptor agonists. An opportunity for individualized therapy].
    Jódar E
    Med Clin (Barc); 2014; 143 Suppl 2():12-7. PubMed ID: 25326838
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluating second-line treatment options for type 2 diabetes: focus on secondary effects of GLP-1 agonists and DPP-4 inhibitors.
    Boland CL; Degeeter M; Nuzum DS; Tzefos M
    Ann Pharmacother; 2013 Apr; 47(4):490-505. PubMed ID: 23548652
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical efficacy and safety of once-weekly glucagon-like peptide-1 agonists in development for treatment of type 2 diabetes mellitus in adults.
    Tzefos M; Harris K; Brackett A
    Ann Pharmacother; 2012 Jan; 46(1):68-78. PubMed ID: 22232377
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Glucagon-Like Peptide-1 Receptor Agonists and Strategies To Improve Their Efficiency.
    Alavi SE; Cabot PJ; Moyle PM
    Mol Pharm; 2019 Jun; 16(6):2278-2295. PubMed ID: 31050435
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Risk of heart failure hospitalization among users of dipeptidyl peptidase-4 inhibitors compared to glucagon-like peptide-1 receptor agonists.
    Dawwas GK; Smith SM; Park H
    Cardiovasc Diabetol; 2018 Jul; 17(1):102. PubMed ID: 30016946
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.